focus -WSS

focus

author：leisure time 2025-10-01 23:47:42 Page View：84

close-up of psoriasis on a hand. -- biotech coverage from STAT — A close-up of psoriasis on a hand. Adobe

San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.

Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.

Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How a billionaire couple greased the skids for Pelosi’s drug pricing bill
Next article： Heart attack and stroke risk calculators need revising

explore

Walensky prepares to leave CDC — and Congress — behind

OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

Big Tobacco's 'harm reduction': Is it for real, or a sham?

TOLGAAKMEN/AFP/GettyImagesThisyearcouldshapeuptobeahistoriconefortobaccocontrol—oroneinwhichBigTobac

Apple is now the first public company to be valued at $3 trillion

6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

Data integrity in scientific journals requires "effort" by publishers, institutions

ScientificwatchdogsSholtoDavid(right)andElisabethBikjoinSTAT'sJonathenWosenattheSTATBreakthroughSumm